Human Insulin Market Research Report – Forecast to 2027

Human Insulin Market Research Report: Information by Type (Traditional Human Insulin and Modern Human Insulin), by Indication (Type 1 Diabetes and Type 2 Diabetes), and by End-User (Hospitals and Clinics and Research Institutes)- Global Forecast Till 2027

ID: MRFR/Pharma/0350-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Human Insulin Market Overview:
Human Insulin Market Analysis: Information by Type (Traditional Human Insulin (Premixed Traditional, Intermediate Acting, and Short-Acting), Modern Human Insulin (Premixed Modern, Long-Acting and Rapid Acting) and Brand (Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin and Insuman)) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Global Forecast till 2025


Market Overview:
Global Human Insulin Market is anticipated to reach USD 90,812.40 million by 2025 to grow CAGR of 12.10% Human Insulin is synthetic insulin which is manufactured in the laboratory, the scientists works on increasing the protein in the insulin. An e.coli bacterium is used to increase the insulin protein. Human insulin can be orchestrated with the help of insulin devices or orally. The devices used for the infusions are insulin pumps, syringes, and injection pens.


Diabetics are considered as disease-related with the lifestyle. As time passes, and with the increase in population rate of the occurrence of diseases has been increased outrageously. 100 Million People approximately around the world need insulin, where the majority of the people are suffering from type 1 diabetes and about 10-25% of people are suffering from diabetic type 2. The approval for the pharmaceutical use of insulin was passed in 1982, however, it was developed way before than that and it’s been in use for the last 90 years to treat diabetic patients. The focal point of insulin is on managing the sugar levels in the blood. 


The growth of the global insulin market is determined by a number of factors including rising obesity endemic, increasing prevalence of diabetics, the advancement of technologies, increasing a sense of awareness among the people, and rise in the geriatric population. Apart from this, the high rising cost of the insulin analog and the legislative demand for the acceptance of insulin hamper the growth in the market for insulin.


This report focuses on the overall insulin market analysis and intensity by explaining the human insulin market. Apart from that, the report contains the peaks of the market dynamics, segmentation, key players, regional analysis, and many other factors. From the past few years, the market was gigantic for human insulin.


Covid 19 Analysis:
The world economic growth is at stake due to the covid 19 pandemic and the global human insulin market is no exception. There are various steps taken by the government to solve the issue, the vaccination is also available in the market. The Government is continuously working so that the companies can resume operations for private and government business.


The Human insulin market has agonized an unquestionable impact but the market is able to maintain relatively positive growth. The insulin market is able to maintain an average growth rate of 15 from million USD in 2014 to million USD in 2019, on the annual basis. The analysts believe that the market will expand in the future and by the end of 2025, it will show tremendous result. The size of the market will expand and reach up to a million USD.


Market Dynamic:
Market Outline
The global market for modern human insulin is steered up by the increasing demand of insulin due to the increase or assurance of the diabetic Mellitus. Apart from this, the modern innovative technologies and rising awareness among the people have also driven the market. The screening of the DM which is diabetic Mellitus can also be considered as an important factor here.


There are new treatments option which are available for diabetic patients, which is ultimately emphasizes the growth of the market. Along with that, the rising geriatric population can also be considered as a major cause, which accelerates the market growth.


Key Factors That Navigate the Human Insulin Market:
Diabetics are a non-transmissible and chronic disease which is rising enormously with the rise in the population. According to the researches, it is one of the major causes of death rates in the whole world, which is increasing the possibility of a number of serious health problems. This particular disease can triggers other diseases and causes strokes, eye disorders, cardiovascular disease, and different kidney diseases. 


In 2019 may, an insulin lispro injection was launched; this is a rapid-acting insulin that comes at a lower cost. The company is selling the insulin at 50% less price as compare to the similar medicine Humalog U-100. According to the national diabetic statistic reports of 2017, in US, there are more than 100 million people who are suffering from diabetics or who have prediabetes.


An Expected Growth Of 12% at CAGR During The Prophesy Period:
There are basically two different segments of the human insulin market industry, one is modern human insulin and another is traditional human insulin. The traditional segment has intermediate-acting, short-acting, and premixed traditional, whereas the modern segment includes long-acting, rapid-acting, and premixed modern.


Modern insulin which is the customized version of traditional insulin is leading the segment since 2018. Modern insulin is a prescribed medicine preferred by doctors globally for the diabetic patients. It gives better results which are more effective as compare to the traditional segment.


Segmentation (On the basis of the type):



  •         The human insulin market trends are categorized on the basis of indication, type, and end-users, globally.

  •         Depending on the type the device or accessories are selected

  •         By following different methods, it is segmented into the modern human insulin and traditional human insulin.

  •         On the application basis, it is segmented into type 1 diabetic and type 2 diabetic.

  •         Lastly, it is segmented into the research lab, forensic laboratories, and others, which is on the basis of the end-users


Demand for the treatment services and diagnosis, on the basis of regional analysis:
The United States is the biggest market for human insulin, followed by South America, Canada. South America and Canada are the fastest growing insulin market sectors. The contribution of the major players in the development activities and researches will also magnify the growth of the annual market size of human insulin, in the review period through funding.


The funding for the diagnosis of the diseases, the involvement of the majority of the population into the disease through one way or another, and the treatment procedure has driven the European market for insulin. On the other hand, the government of Germany is struggling to support the researches, high demand for human insulin and for the development activities. Asia pacific insulin market is the fastest growing insulin market where the huge population can be considered as the base cause. The contribution of the countries like India, China, and Japan has raised the growth of the market here.


The sudden increase in the growth of the human insulin markets in these regions is due to the poor lifestyle, unhealthy habits and obesity where there is a lack of physical activities, the majority of the population is at health threat. The bad economic condition and less developed countries that have fewer medical facilities, demands for the services and diagnosis of a treatment. 


Top Brands and key Players:
 The major brand in the human insulin market share is Lantus, after the loss of patent, in the form of the biosimilar, the drug got some completion, named basaglar from Eli Lilly. In April 2015, Toujeo launched its drug who is been shifting from one patients to another to lessen the revenue of lantus.


The major key players of the insulin market share by company are Tonghua Dongbao Pharmaceuticals Co.Ltd, Bio con Ltd, Inc, Bristol-Myers Squibb Company, ADOCIA, Glaxo SmithKline, Julphar, Merck & Co, Pfizer, Oramed Pharmacuticals, Inc, Sonofi, and Novo Norddisk A/S.


Recent Developments:



  •         Human insulin market projected to reach USD 39.13 Billion by 2020 with a speed of CAGR 8.1% from 2015 to 2020

  •         Base year is 2014


Report Overview:



  •         Market Overview

  •         Covid 19 Analysis

  •         Market Dynamic

  •         Market Outline

  •         Key Factors That Navigate The Human Insulin Market

  •         An Expected Growth Of 12% At CAGR During The Prophesy Period

  •         Segmentation (On the basis of the type)

  •         Demand for the treatment services and diagnosis, on the basis of regional analysis

  •         Top Insulin Brands and key Players

  •         Top Insulin Brands and key Players

  •         Recent Developments


The report is to point out the high points of the human insulin market in terms of the revenue hike by end of the global forecast year 2025


Global Insulin Market by Regions Basis:
Americas



  •         North America

  •         US

  •         Canada

  •         Latin America


Europe:



  •         Western Europe

  •         Germany

  •         France

  •         Italy

  •         UK

  •         Spain

  •         Rest of western Europe

  •         Eastern Europe


Pacific Asia:



  •         Japan

  •         China

  •         Australia

  •         India

  •         South Korea

  •         Rest of Pacific-Asia


Middle East & Africa



  •         Middle east

  •         Africa


 Deliberated audience:



  •         Market Researcher and consulting services providers

  •         Potential investors

  •         Pharmaceuticals manufacturers and suppliers

  •         Researches and development (R&D) Companies

  •         Medical research laboratories



Frequently Asked Questions (FAQ) :


In 2017 the market size of the insulin market was USD 10.6 billion and the market is expected growth of CAGR of 4.29% during the forecast period 2020 to 2025

Sanofi, Eli Lilly, and Novo Nordisk are three massive pharmaceutical companies with a majority of 27 billion global insulin market.

A new rapid-acting meal-time insulin named Lyumjev is approved by FDA.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Human Insulin Market, by Type

6.1 Introduction

6.2 Traditional Human Insulin

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Modern Human Insulin

6.3.1 Market Estimates & Forecast, 2020-2027

7. Global Human Insulin Market, by Indication

7.1 Introduction

7.2 Type 1 Diabetes

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Type 2 Diabetes

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Human Insulin Market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research Institutes

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Human Insulin Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Biocon Ltd

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.2 Tonghua Dongbao Pharmaceuticals Co., Ltd.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.3 Merck & Co.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.4 ADOCIA

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.5 Pfizer

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Bristol-Myers Squibb Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 GlaxoSmithKline

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Human Insulin Industry

14 Appendix

LIST OF TABLES

Table 1 Human Insulin Industry Synopsis, 2020-2027

Table 2 Global Human Insulin Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Human Insulin Market, by Region, 2020-2027, (USD Million)

Table 4 Global Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 5 Global Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 6 Global Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 7 North America Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 8 North America Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 9 North America Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 10 U.S. Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 11 U.S. Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 12 U.S. Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 13 Canada Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 14 Canada Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 15 Canada Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 16 South America Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 17 South America Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 18 South America Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 19 Europe Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 20 Europe Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 21 Europe Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 22 Western Europe Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 23 Western Europe Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 24 Western Europe Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 25 Eastern Europe Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 26 Eastern Europe Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 27 Eastern Europe Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 28 Asia Pacific Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 29 Asia Pacific Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 30 Asia Pacific Human Insulin Market, by End-User, 2020-2027, (USD Million)

Table 31 Middle East & Africa Human Insulin Market, by Type, 2020-2027, (USD Million)

Table 32 Middle East & Africa Human Insulin Market, by Indication, 2020-2027, (USD Million)

Table 33 Middle East & Africa Human Insulin Market, by End-User, 2020-2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Human Insulin Market

Figure 3 Segmentation Market Dynamics for Human Insulin Market

Figure 4 Global Human Insulin Market Share, by Type 2020

Figure 5 Global Human Insulin Market Share, by Indication 2020

Figure 6 Global Human Insulin Market Share, by End-User, 2020

Figure 7 Global Human Insulin Market Share, by Region, 2020

Figure 8 North America Human Insulin Market Share, by Country, 2020

Figure 9 Europe Human Insulin Market Share, by Country, 2020

Figure 10 Asia Pacific Human Insulin Market Share, by Country, 2020

Figure 11 Middle East & Africa Human Insulin Market Share, by Country, 2020

Figure 12 Global Human Insulin Market: Company Share Analysis, 2020 (%)

Figure 13 Biocon Ltd: Key Financials

Figure 14 Biocon Ltd: Segmental Revenue

Figure 16 Biocon Ltd: Geographical Revenue

Figure 17 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Key Financials

Figure 18 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Segmental Revenue

Figure 19 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Geographical Revenue

Figure 20 GlaxoSmithKline plc: Key Financials

Figure 21 GlaxoSmithKline plc: Segmental Revenue

Figure 22 GlaxoSmithKline plc: Geographical Revenue

Figure 23 ADOCIA, INC.: Key Financials

Figure 24 ADOCIA, INC.: Segmental Revenue

Figure 25 ADOCIA, INC.: Geographical Revenue

Figure 26 Pfizer: Key Financials

Figure 27 Pfizer: Segmental Revenue

Figure 28 Pfizer: Geographical Revenue

Figure 29 Bristol-Myers Squibb Company: Key Financials

Figure 30 Bristol-Myers Squibb Company: Segmental Revenue

Figure 31 Bristol-Myers Squibb Company: Geographical Revenue